Issued on behalf of Aleen Inc.
VANCOUVER – Baystreet.ca News Commentary – AI-powered wellness platforms are commercializing rapidly as major technology companies launch personalized health coaching systems at scale[1]. The global wellness technology market is accelerating toward $50 billion by 2025[2] with AI-driven applications capturing significant share as consumer adoption creates expanding revenue opportunities for companies positioned at the intersection of artificial intelligence and digital wellness. Several publicly traded companies developing AI-powered health interpretation platforms and personalized wellness solutions stand to benefit from this market expansion, including Aleen Inc. (CSE: ALEN-U), Caris Life Sciences, Inc. (NASDAQ: CAI), Accenture plc (NYSE: ACN), Certara, Inc. (NASDAQ: CERT), and Zimmer Biomet Holdings, Inc. (NYSE: ZBH).
Corporate wellness spending is shifting toward AI-driven personalization with organizations deploying machine learning algorithms that deliver measurable cost reductions through proactive preventive care strategies[3]. Patient engagement platforms integrating predictive analytics are capturing market share by improving patient compliance through gamification and AI-powered recommendations, creating favorable conditions for companies offering digital wellness solutions that address accelerating demand across consumer and enterprise markets[4].
Aleen Inc. (CSE: ALEN-U), a Canadian technology company operating in the digital wellness space, has announced it is beginning early concept testing for smart wellness analytics, building on its previous initiative to enhance personalized interpretation of wellness information. The company is exploring how analytical tools could help users recognize trends and behavior patterns in their wellness data over time, while remaining entirely outside clinical or diagnostic functions.
"Our current focus is on understanding how an analytical tool can responsibly support everyday well-being — while staying entirely outside the realm of diagnostic or medical functions," said Anastasiia Kalashnik, PR Specialist of Aleen Inc. "We are laying the groundwork for a feature that inspires awareness and self-reflection, not prescribes actions."
Based in Ontario, Aleen Inc. went public on the Canadian Securities Exchange in June 2025 and has developed an AI platform designed to help users understand their inputs and wellness indicators. The current testing phase focuses on assessing real user needs and expectations, exploring potential analytical approaches that could simplify recognition of trends over time, and conducting scenario-based evaluations to understand how structured insights might enhance personal well-being awareness.
Aleen Inc. operates in a rapidly expanding market. The global digital wellness sector is currently valued at approximately $12.87 billion in 2025 and is projected to grow to $45.65 billion by 2034, representing annual growth of 15.1%. With about 57% of consumers now using digital apps and wearable devices to monitor their well-being, Aleen Inc. is positioned to capture a portion of this expanding demand.
The Aleen AI system can be accessed in two ways. Users can visit the Aleen website for free wellness insights, which helps raise awareness and encourages active engagement with personal well-being. Businesses can integrate Aleen Inc.'s technology via its API, allowing wellness apps and digital platforms to embed the AI-powered insights into their own services.
The company generates revenue through its API offerings, available through a per-call option for businesses paying only for requests used, and a monthly subscription for consistent access. Looking ahead to 2026, Aleen Inc. plans to launch personal user accounts that will allow individuals to securely store and organize their wellness information in one place, alongside introducing the smart analytics features currently in early testing.
To fund these initiatives, Aleen Inc. is currently seeking between $20 million and $30 million in strategic investment. The company plans to allocate 35% of these funds toward technology development, 30% toward sales and marketing efforts, and 20% for product expansion including mobile apps and specialized modules for corporate wellness programs.
The company emphasizes that its platform is designed for preliminary wellness insights only and is not intended to replace consultations with healthcare professionals. Aleen Inc. does not provide medical diagnoses and is not regulated as a medical device by the FDA or other health authorities.
With 12,643,300 common shares currently issued and outstanding, Aleen Inc. continues to build its presence in the digital wellness space under the leadership of CEO Inna Aksman.
CONTINUED… Read this and more news for Aleen Inc. at: https://usanewsgroup.com/2025/10/25/ai-engine-replaces-the-waiting-room-powering-the-660b-health-revolution/
Caris Life Sciences (NASDAQ: CAI) has announced collaborative research validating TET2 clonal hematopoiesis as a promising biomarker for improved response to immune checkpoint inhibitor therapy in patients with solid tumors. The study leveraged Caris Life Sciences' extensive clinico-genomic database, analyzing outcomes in nearly 36,000 patients with non-small cell lung cancer and over 25,000 colorectal cancer patients to provide large-scale evidence supporting TET2-CH as a potential biomarker for enhanced ICI response.
"These findings represent a major step forward in understanding how clonal hematopoiesis influences cancer immunology," said Milan Radovich, PhD, Senior Vice President, Chief Scientific Officer at Caris. "It further demonstrates that we are only scratching the surface on the potential applications of CH, namely a novel function of CH as a predictive therapeutic biomarker that can be used to improve patient outcomes."
This research represents a major observation that directly ties clonal hematopoiesis to therapy outcomes in solid tumors, suggesting a future role of CH for driving therapy selection. The findings were published in Cancer Cell as part of collaborative research led by Padmanee Sharma, MD, PhD at the James P. Allison Institute at The University of Texas MD Anderson Cancer Center.
Accenture (NYSE: ACN) has acquired Decho, a UK-based technology and AI consultancy that helps organizations reinvent through the design, delivery and scaling of Palantir solutions. The acquisition strengthens Accenture's strategic advisory and advanced engineering capabilities for Palantir solutions for clients across the health, government, defense and commercial sectors in the UK and beyond.
"Gen AI has enormous potential but needs the right platform and expertise to deliver real outcomes," said Bryan Rich, global Data and AI lead for Health and Public Service at Accenture. "Decho is uniquely positioned to provide capabilities required in the most demanding industries with their combined Palantir and gen AI expertise, strong ecosystem relationships and proprietary products."
Decho brings a team of over 40 specialist engineers with expertise across Palantir platforms, including its Foundry and Artificial Intelligence Platform, and will be integrated into Accenture's Data and AI organization in the UK. By combining Accenture's advanced data and AI capabilities with Decho's expertise in deploying and operationalizing data and AI platforms using Palantir, the acquisition helps organizations realize the full value of their architecture, data, software and AI.
Certara (NASDAQ: CERT) has joined the Veeva AI Partner Program to simplify digital data flows between Veeva RIM and Certara's CoAuthor generative AI solution for regulatory and medical writing. The planned integration aims to significantly enhance document automation by allowing regulatory writers using CoAuthor and Veeva RIM to seamlessly work in both systems, directly linking source files from Veeva RIM without importing them into CoAuthor.
"Medical writers are embracing generative AI like CoAuthor to cut first-draft time by 30%. The integration with Veeva Rim allows us to deliver a seamless, end-to-end regulatory writing experience that drives greater value," said Christopher Bouton, Chief Technology Officer at Certara.
This integration addresses a significant roadblock for regulatory writers by providing seamless access to content between data preparer, technology, and writer throughout the document draft life cycle. Certara accelerates medicines using biosimulation software, technology, and services to transform traditional drug discovery and development, serving more than 2,400 biopharmaceutical companies, academic institutions, and regulatory agencies across 70 countries.
Zimmer Biomet Holdings (NYSE: ZBH) has completed the acquisition of Monogram Technologies Inc., an AI-driven, next-generation orthopedic robotics company, creating the broadest, most flexible portfolio of orthopedic robotics and navigation technologies. Monogram's surgeon-guided semi- and fully autonomous robotic technologies are expected to add new and differentiated capabilities to Zimmer Biomet's already broad suite of customer-centric technology solutions.
"By bringing Monogram into the Zimmer Biomet innovation ecosystem, we have set a bold course to become the first orthopedic company to offer a fully autonomous robotic solution complementing our current robotic and navigation offerings," said Ivan Tornos, Chairman, President and CEO of Zimmer Biomet. "We aim to provide surgeons the broadest choice in robotics and navigation across a wide range of procedures and care settings."
Monogram has developed a CT-based, semi-autonomous, AI-navigated total knee arthroplasty robotic technology, which received FDA 510(k) clearance in March 2025 and is expected to be commercialized with Zimmer Biomet implants by early 2027. Additionally, Monogram began conducting a clinical study in July 2025 for the fully autonomous version of its technology, with the acquisition completed at $4.04 per share in cash plus contingent value rights entitling holders to receive up to $12.37 in cash if certain product development, regulatory and revenue milestones are achieved through 2030.
Article Sources: https://usanewsgroup.com/2025/10/25/ai-engine-replaces-the-waiting-room-powering-the-660b-health-revolution/
CONTACT:
Baystreet.ca
[email protected]
(805) 649-0042
DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for Aleen Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares Aleen Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Aleen Inc. which were purchased in the open market. MIQ reserves the right to buy and sell, and will buy and sell shares of Aleen Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. Aleen’s solutions operate within the wellness domain and are not subject to FDA or Health Canada approval. The platform provides wellness insights based on user inputs and is not intended to diagnose, treat, or prevent any medical condition.
--
SOURCES CITED:
1. https://research.google/blog/how-we-are-building-the-personal-health-coach/
2. https://globalwellnessinstitute.org/global-wellness-institute-blog/2025/04/02/ai-initiative-trends-for-2025/
3. https://capefoxfcg.com/mediacenter/the-role-of-ai-in-personalized-employee-health-programs-a-2025-perspective/
4. https://www.pharmiweb.com/press-release/2025-10-24/patient-engagement-solutions-market-research-size-share-growth-trends-and-forecast-to-2029
